A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Fixed-Dose Combinations of GSK3640254 and Dolutegravir and to Assess the Effect of Food on the Select Fixed Dose Combination of GSK3640254 and Dolutegravir in Healthy Participants
Latest Information Update: 14 Mar 2024
Price :
$35 *
At a glance
- Drugs Dolutegravir/GSK 3640254 (Primary) ; Fipravirimat (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 21 Sep 2021 Status changed from recruiting to completed.
- 02 Jun 2021 Planned End Date changed from 1 Sep 2021 to 25 Aug 2021.
- 02 Jun 2021 Planned primary completion date changed from 1 Sep 2021 to 25 Aug 2021.